Although direct evidence in PC is still limited, the genetic and molecular similarities between prostate, breast, and ovarian cancers support further exploration of redox and epigenetic therapies in PC, particularly in molecularly defined subgroups with GSTM5 dysregulation [39,40]. This evidence concerns the gene GSTM5 and ovarian cancer.